In a recent retrospective study of carboplatin and paclitaxel for cisplatin ineligible HNSCC patients, did this combo have less toxicity?
What was the increase in median radiographic PFS in the GROUQ-PCS 9 trial of SBRT for oligometastatic CRPC?
What was the rate of PFS at 2 years with de-escalated adjuvant therapy among HNSCC patients with extranodal extension in the MC1675 trial?
Answers
What was the increase in median radiographic PFS in the GROUQ-PCS 9 trial of SBRT for oligometastatic CRPC?
What was the rate of PFS at 2 years with de-escalated adjuvant therapy among HNSCC patients with extranodal extension in the MC1675 trial?
Answers
Not really. Though disease outcomes were similar, the rates of toxicity were actually higher with carbo/taxol than cisplatin.
Doubled from 2.3 to 4.6 months. Progressionhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00351-1/abstract at original sites of disease was reduced from 76% without SBRT to 12%.
81.1% v 97.4% with standard adjuvant chemoradiation. The de-escalated arm used 30-36 Gy in 20 BID fractions with concurrent docetaxel, and it was associated with less chronic toxicity. | QuadShot News